Wellgistics Health filed an 8-K (reported April 9, 2026) announcing the termination of its Section 3(a)(10) settlement agreement with Silverback Capital Inc., effective after issuing approximately 6.87 million shares. The company delivered notice to end the arrangement (originally tied to events around April 3), citing pursuit of alternative strategic and financing initiatives. This directly removes the ongoing dilution overhang that had pressured the microcap penny stock. The filing triggered strong momentum buying in after-hours trading on April 9 (with volume exceeding 30 million shares) and carried into premarket on April 10, lifting the stock roughly 54-62% from its April 9 close near $0.106. As a low-float, volatile name with a history of sharp moves on company-specific news (including recent note financings and the earlier Neuritek LOI), the elimination of future dilution acted as a clear positive catalyst, amplified by retail trader interest. No other major new announcements align precisely with the timing.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.